Multimodal multiobjective optimization with structural network control principles to optimize personalized drug targets for drug discovery of individual patients.

Structural network control principles provided novel and efficient clues for the optimization of personalized drug targets (PDTs) related to state transitions of individual patients. However, most existing methods focus on one subnetwork or module as drug targets through the identification of the minimal set of driver nodes and ignore the state transition capabilities of other modules with different configurations of drug targets [i.e. multimodal drug targets (MDTs)] embedding the knowledge of previous drug targets (i.e. multiobjective optimization). Therefore, a novel multimodal multiobjective evolutionary optimization framework (called MMONCP) is proposed to optimize PDTs with network control principles. The key points of MMONCP are that a constrained multimodal multiobjective optimization problem is formed with discrete constraints on the decision space and multimodality characteristics, and a novel evolutionary algorithm denoted as CMMOEA-GLS-WSCD is designed by combining a global and local search strategy and a weighting-based special crowding distance strategy to balance the diversity of both objective and decision space. The experimental results on three cancer genomics data from The Cancer Genome Atlas indicate that MMONCP achieves a higher performance including algorithm convergence and diversity, the fraction of identified MDTs, and the area under the curve score than advanced algorithms. Additionally, MMONCP can detect the early state from the difference between the target activity and toxicity of MDTs and provide early treatment options for cancer treatment in precision medicine.